As the cannabis industry matures, the conversation is shifting from basic intoxication to precise, effect-based wellness. But how do we bridge the gap between consumer anecdotes and true scientific validation for minor cannabinoids?

About This Episode

In this episode of High Spirits, Ben Larson and AnnaRae Grabstein sit down with Alleh Lindquist, CEO of FloraWorks, to explore the rapidly evolving landscape of minor cannabinoids. Alleh shares how FloraWorks transitioned from a wholesale supplier to a clinical research pioneer, paving the way for CBN to become a mainstream, trusted ingredient in the global wellness market. They dive deep into the regulatory hurdles of the upcoming hemp landscape, the reality of running a 1,000+ person clinical trial, and the incredible therapeutic potential of CBN beyond sleep.

What You’ll Learn

• The Clinical Blueprint for Cannabinoids: Why a 50mg dose of pure CBN outperformed melatonin in a landmark double-blind, placebo-controlled sleep study—and what this means for product formulation.
• Navigating the Regulatory Gray Zone: How to structurally and legally position structure-function claims (like "improving sleep quality") on product packaging without triggering FDA disease claims.
• The Future of Cannabinoid Research: A look into FloraWorks’ ground-breaking collaboration with the Salk Institute, where CBN is showing massive potential in reversing age-related cognitive decline and protecting neural pathways.
• Embracing Uncertainty as a Leader: Actionable advice on how operators can survive current market instability while building a 10-year vision for a stigma-free, mature industry.

Meet the Guest

Alleh Lindquist is the CEO of FloraWorks, a specialized cannabinoid data and technology company dedicated to the clinical verification and commercialization of minor cannabinoids. Under his leadership, FloraWorks has standardized its patented manufacturing processes to approach FDA dietary ingredient pathways and pioneered massive real-world evidence trials. Alleh is a recognized voice in navigating frontier markets, dedicated to collaborating with researchers, clinicians, and major brands to professionalize the cannabinoid supply chain.

Why Tune In?

If you are an operator, entrepreneur, or investor looking to understand how the cannabinoid market will survive shifting regulations and integrate into the broader healthcare and dietary supplement spaces, this conversation provides the ultimate scientific and strategic roadmap.

Have a question for us? Send us a text. We may answer it in the next show!

--
High Spirits is brought to you by Vertosa and Wolf Meyer.

Your hosts are Ben Larson and AnnaRae Grabstein.

Follow High Spirits on LinkedIn.

We'd love to hear your thoughts. Who would you like to see on the show? What topics would you like to have us cover?

Visit our website www.highspiritspod.com and listen to all of our past shows.

THANK YOU to our audience. Your engagement encourages us to keep bringing you these thought-provoking conversations.

Remember to always stay curious, stay informed, and most importantly, keep your spirits high.